Revenue growth of India's pharmaceutical sector is expected to "moderate" to 9 per cent in FY22, as compared with a healthy rise of 12.5 per cent during the previous fiscal, Crisil said
from Latest News https://ift.tt/3ckYxQC
Tuesday, 16 November 2021
Sluggish exports may cap pharma YoY revenue growth in FY22, says Crisil
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment